News
Galapagos Plans Clinical And Translational Data Presentations At EBMT Congress 2024
4 Apr 24
News
Galapagos Downgraded, Pharma Firm Faces Uphill Battle With Slow Pipeline Progress: Analyst
1 Apr 24
Analyst Color, Biotech, News, Downgrades, Health Care, Top Stories, General
B of A Securities Downgrades Galapagos to Underperform, Lowers Price Target to $31
28 Mar 24
News, Downgrades, Price Target, Analyst Ratings
Morgan Stanley Assumes Galapagos at Equal-Weight, Announces Price Target of $38
7 Mar 24
News, Price Target, Initiation, Analyst Ratings
Earnings Scheduled For February 22, 2024
22 Feb 24
Earnings
Galapagos To Present New Preliminary Translational Data And Previously Disclosed Data From EUPLAGIA-1 Phase 1/2 Study At The European Society For Blood And Marrow Transplantation - 8K
16 Feb 24
News, Health Care, General
Press releases
Galapagos showcases innovative approach in hematological cancer care with clinical and translational data presentations at EBMT congress 2024
4 Apr 24
News, Press Releases
Galapagos appoints Andrew Dickinson as Non-Executive Non-Independent Director to its Board
26 Mar 24
News, Press Releases
Frontier Medicines Announces Oversubscribed $80 Million Series C Financing to Support Progress of Clinical-Stage Pipeline
22 Feb 24
News, Financing, Press Releases
Galapagos announces full year 2023 results and outlook for 2024
22 Feb 24
News, Press Releases
Galapagos presents at EBMT-EHA annual meeting 2024
15 Feb 24
News, Press Releases
NodThera Announces Appointment of Dr. Thomas Jaecklin as Chief Medical Officer
5 Feb 24
Press Releases
Galapagos completes transaction to transfer Jyseleca® business to Alfasigma
31 Jan 24
News, Press Releases